Dr. Jennifer M. Scalici

Oncology
5673 Peachtree Dunwoody Road, Fl7, 
Atlanta, GA 
21 Years of Experience
5673 Peachtree Dunwoody Road, Fl7, 
Atlanta, GA 
OverviewInsuranceLocationsClinical Research

Overview

Jennifer Scalici is an Oncologist in Atlanta, Georgia. Dr. Scalici has been practicing medicine for over 21 years and is rated as an Experienced provider by MediFind in the treatment of Vaginal Agenesis. Her top areas of expertise are Ovarian Cancer, Cervical Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, and Lymphadenectomy.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Alabama - Birmingham, School Of Medicine, 2005.0
Residency
Northwestern Medicine Prentice Women's Hospital
Specialties
Oncology
Licenses
Obstetrics & Gynecology in IL
Board Certifications
American Board Of Obstetrics And Gynecology, 2015
Fellowships
University of Virginia Health System
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Emory Decatur Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Emory Women's Center at Emory Saint Joseph's Hospital
5673 Peachtree Dunwoody Road, Fl7, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Radiation, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
View 2 Less Clinical Trials

38 Total Publications

Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191].
Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191].
Journal: Gynecologic oncology
Published: November 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scalici's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile